REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,773.50
Bid: 1,772.00
Ask: 1,772.50
Change: 12.50 (0.71%)
Spread: 0.50 (0.028%)
Open: 1,770.00
High: 1,776.00
Low: 1,766.00
Prev. Close: 1,761.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM

5 May 2021 18:23

RNS Number : 6938X
GlaxoSmithKline PLC
05 May 2021
 

GlaxoSmithKline plc

 

Results of Annual General Meeting

 

GlaxoSmithKline plc ('GSK') held its Annual General Meeting ('AGM') at 2.30pm on Wednesday 5 May 2021.

 

The statement made by the Chairman at the AGM will shortly be available to view on GSK's website at www.gsk.com.

 

All valid proxy votes (whether submitted electronically or in hard copy form) were included in the poll taken at the meeting.

 

The table below shows the results of the poll on all 22 resolutions. The full text of the resolutions is contained in the Notice of AGM published on 30 March 2021, which is available on GSK's website at www.gsk.com.

 

 

Resolution

Total votes for(1)(2)

%

Total votes against(2)

%

Total votes cast

Votes withheld(3)

1

Receive and adopt the 2020 Annual Report

3,475,135,362

98.81

41,757,734

1.19

3,516,893,096

11,603,440

2

Approve the Annual report on remuneration

3,272,132,033

93.14

240,932,159

6.86

3,513,064,192

15,444,148

3

Re-election of Sir Jonathan Symonds

3,499,343,831

99.52

16,763,629

0.48

3,516,107,460

12,371,547

4

Re-election of Dame Emma Walmsley

3,507,017,955

99.68

11,159,384

0.32

3,518,177,339

10,359,075

5

Re-election of Charles Bancroft

3,506,975,009

99.74

9,026,131

0.26

3,516,001,140

12,472,435

6

Re-election of Vindi Banga

3,496,064,409

99.43

19,904,292

0.57

3,515,968,701

12,509,463

7

Re-election of Dr Hal Barron

3,507,018,967

99.69

10,733,599

0.31

3,517,752,566

10,738,305

8

Re-election of Dr Vivienne Cox

3,497,451,811

99.46

18,813,391

0.54

3,516,265,202

12,207,081

9

Re-election of Lynn Elsenhans

3,434,728,312

97.69

81,301,678

2.31

3,516,029,990

12,440,783

10

Re-election of Dr Laurie Glimcher

3,508,174,526

99.77

7,947,259

0.23

3,516,121,785

12,353,907

11

Re-election of Dr Jesse Goodman

3,506,872,640

99.74

9,131,605

0.26

3,516,004,245

12,467,159

12

Re-election of Iain Mackay

3,501,889,913

99.56

15,637,087

0.44

3,517,527,000

10,951,129

13

Re-election of Urs Rohner

3,484,061,208

99.10

31,702,634

0.90

3,515,763,842

12,752,529

14

Re-appointment of the auditor

3,512,936,007

99.84

5,521,996

0.16

3,518,458,003

10,024,350

15

Remuneration of the auditor

3,511,280,034

99.82

6,176,678

0.18

3,517,456,712

11,022,183

16

Authority for the company to make donations to political organisations and incur political expenditure

3,440,815,513

98.36

57,276,887

1.64

3,498,092,400

30,393,327

17

Authority to allot shares

3,362,807,250

95.66

152,632,653

4.34

3,515,439,903

13,038,799

18

Disapplication of pre-emption rights - general power(4)

3,368,593,428

95.88

144,660,127

4.12

3,513,253,555

15,222,364

19

Disapplication of pre-emption rights - in connection with an acquisition or specified capital investment(4)

3,291,504,396

93.68

221,978,886

6.32

3,513,483,282

14,999,454

20

Authority for the company to purchase its own shares(4)

3,449,168,275

98.36

57,436,714

1.64

3,506,604,989

21,875,135

21

Exemption from statement of senior statutory auditor's name

3,477,878,016

99.47

18,543,893

0.53

3,496,421,909

31,294,363

22

Authority for reduced notice of a general meeting other than an AGM(4)

3,286,542,818

93.50

228,494,172

6.50

3,515,036,990

12,675,849

 

 

Notes:

 

(1)

The "for" votes include those giving the Chairman discretion. In line with the notification issued to American Depositary Receipt (ADR) holders last year, GSK did not instruct its ADR Depositary to vote any unvoted ADRs in respect of the AGM resolutions.

(2)

Votes "for" and "against" are expressed as a percentage of the total votes cast.

(3)

A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "for" or "against" a resolution.

(4)

Indicates Special Resolutions requiring a 75% majority.

 

The following table provides further relevant information:

 

 

 

GSK's

Twenty first

AGM

(2021)

 

GSK's

Twentieth

AGM

(2020)

Issued share capital (excluding Treasury Shares)

5,031,444,276

5,017,091,542

Total votes cast and votes withheld lodged as a % of GSK's issued share capital (excluding Treasury Shares)

70.11%

72.60%

Total shareholder population

100,906

105,353

Total number of proxies lodged

6,089

6,268

% of shareholders who lodged proxies

6.03%

5.95%

 

The above poll results will shortly be available on the company's website at www.gsk.com. In accordance with Listing Rule 9.6.2, a copy of the resolutions, other than those concerning ordinary business, will be submitted to the UK Listing Authority and will in due course be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism 

 

 

V A Whyte

Company Secretary

 

5 May 2021

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGDKPBBOBKDDPK
Date   Source Headline
8th May 20246:21 pmRNSResult of AGM
8th May 20244:57 pmRNSBoard Committee Change
3rd May 20243:30 pmRNSDirector/PDMR Shareholding
1st May 20243:00 pmRNSTotal Voting Rights
1st May 20247:00 amRNS1st Quarter Results
24th Apr 20247:00 amRNSUS FDA accepts new indication filing for Jemperli
19th Apr 20243:30 pmRNSDirector/PDMR Shareholding
17th Apr 20243:30 pmRNSDirector/PDMR Shareholding
17th Apr 20247:05 amRNSGSK announces additional EAGLE-1 results
17th Apr 20247:00 amRNSResults from long-term data relating to Shingrix
16th Apr 20242:11 pmRNSAmendment - Director/PDMR Shareholding
16th Apr 20247:00 amRNSFDA accepts GSK meningitis vaccine candidate file
15th Apr 20243:30 pmRNSDirector/PDMR Shareholding
4th Apr 202412:05 pmRNSReplacement - Total Voting Rights
2nd Apr 20243:00 pmRNSTotal Voting Rights
26th Mar 20243:30 pmRNSDirector/PDMR Shareholding
25th Mar 20241:00 pmRNSNotice of AGM
22nd Mar 20244:20 pmRNSTransfer of Treasury Shares
22nd Mar 20243:36 pmRNSDirector/PDMR Shareholding
18th Mar 20249:30 amRNSNew Phase III Jemperli data in endometrial cancer
13th Mar 20243:48 pmRNSDirector/PDMR Shareholding
8th Mar 20245:12 pmRNSBoard Committee Change
7th Mar 20247:00 amRNSGSK announces positive Blenrep DREAMM-8 results
6th Mar 20244:00 pmRNSViiV LAI vs oral SOC data in adherence-challenged
5th Mar 20245:24 pmRNSGSK Annual Report 2023 on Form 20-F
5th Mar 20247:00 amRNSNew ViiV LA formulation potential 4-month dosing
1st Mar 20243:00 pmRNSTotal Voting Rights
1st Mar 202412:15 pmRNSGSK publishes Annual Report 2023
29th Feb 20247:05 amRNSDirectorate Change
29th Feb 20247:00 amRNSStatement: Zantac (ranitidine) litigation
26th Feb 20243:30 pmRNSDirector/PDMR Shareholding
26th Feb 20247:00 amRNSGSK announces positive EAGLE-1 headline results
22nd Feb 20243:30 pmRNSDirector/PDMR Shareholding
21st Feb 20247:00 amRNSViiV LAI superior to orals in adherence-challenged
20th Feb 20249:01 amRNSJulie Brown - External Appointment
19th Feb 20243:30 pmRNSDirector/PDMR Shareholding
15th Feb 20243:32 pmRNSDirector/PDMR Shareholding
15th Feb 20247:00 amRNSGSK completes acquisition of Aiolos Bio
13th Feb 20244:45 pmRNSDirector/PDMR Shareholding - Replacement
13th Feb 20243:40 pmRNSDirector/PDMR Shareholding
13th Feb 20243:35 pmRNSDirector/PDMR Shareholding
13th Feb 20243:30 pmRNSDirector/PDMR Shareholding
6th Feb 20247:10 amRNSFDA accepts Arexvy filing for adults 50-59 at risk
6th Feb 20247:05 amRNSShingrix 18+ at risk China filing review accepted
6th Feb 20247:00 amRNSGSK presents positive DREAMM-7 phase III data
1st Feb 20243:30 pmRNSDirector/PDMR Shareholding
1st Feb 20243:00 pmRNSTotal Voting Rights
1st Feb 20247:00 amRNSStatement: Zantac (ranitidine) litigation
31st Jan 20247:00 amRNSFinal Results
29th Jan 20247:05 amRNSEMA accepts Arexvy filing for adults 50-59 at risk

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.